33例结外NK/T细胞淋巴瘤临床分析

杨晓净; 郑波慧; 龚玉萍

33例结外NK/T细胞淋巴瘤临床分析

- 四川大学华西医院血液科(成都, 610041)

详细信息

通讯作者: 龚玉萍,E-mail:gongyuping@hotmail.com

中图分类号: R733.3

收稿日期: 2012-09-28

Clinical analysis of 33 cases of extranodal NK/T-cell lymphoma

- Department of Hematology, Huaxi Hospital, Sichuan University, Chengdu, 610041, China

More Information

Corresponding author: GONG Yuping, E-mail: gongyuping@hotmail.com

Received Date: 28 September 2012

摘要

摘要: 目的：分析结外NK/T细胞淋巴瘤的临床特征、生存时间及影响预后的因素。方法：回顾性分析我院收治的结外NK/T细胞淋巴瘤33例患者的临床资料，分析临床特征、生存时间及影响预后的因素。结果：共收集结外NK/T细胞淋巴瘤患者，男女比例为2：1，发病年龄30~50岁。Ann Arbor分期：Ⅰ期10例（30.3%），Ⅱ期5例（15.2%），Ⅲ期2例（6.06%），Ⅳ期16例（48.5%）。B组患者21例（63.6%），乳酸脱氢酶升高23例（69.7%），血β₂-微球蛋白升高26例（78.8%），病变组织中EBER阳性21例（63.6%）。33例患者中死亡22例，生存11例，中位生存时间12个月，2年总生存（OS）率39.4%。单因素分析结果显示，存在B组症状、体能状况差（ZPS ≥ 2）、LDH/血β₂-微球蛋白升高、EBER阳性、临床分期 ≥ Ⅲ期者预后差。结论：NK/T细胞淋巴瘤患者预后差，影响预后的因素包括B组症状、ZPS评分、LDH/血β₂-微球蛋白水平、EBV感染、临床分期等因素。
- 淋巴瘤 /
- NK/T细胞
Abstract: Objective: The study was aimed to analyze the clinical feature, survival period and prognosis of extranodal NK/T-cell lymphoma retrospectively.Method: 33 cases of extranodal NK/T-cell lymphoma were collected and the clinical feature such as gender, age, clinical stages, laboratory examination were analyzed and survival period and prognosis were summarized.Result: Among 33 cases of NK/T-cell lymphoma, the ratio of male and female patients was 2:1.Age was ranged from 30 to 50 years old.Ann Arbor stagewas as following:10 patients were stageⅠ(30.3%), 5 patients were stageⅡ(15.2%), 2 patients were stage Ⅲ(6.06%), 16 patients were stage Ⅳ(48.5%).21 cases (63.6%) had group B symptoms;Lactate dehydrogenase (LDH) and β₂-microglobulin increased in 23 cases (69.7%) and 26 cases (78.8%) respectively.EBER were positive in 21 cases (63.6%);22 patients died and 11 patients survived.The median survival time was 12 months and overall survival (OS) rate of 2 years was 39.4%;Single factor analysis showed that the patients presenting with symptoms B, physical fitness poor (ZPS ≥ 2), increased LDH/β₂-microglobulin level, positive EBER expression and clinical stages ≥ Ⅲ phase had poor prognosis.Conclusion: The patients with NK/T cell lymphoma had poor prognosis, clinical factors including group B symptoms, ZPS score, LDH/β₂-microglobulin level, EBV infection and clinical stages have an effect on the prognosis of patients.
- lymphoma /
- NK/T-cell

HTML全文

参考文献(11)

[1]	YOK-LAM K.The diagnosis and management of extranodal NK/T-cell lymphoma, nasal-type and aggressive NK-cell leukemia[J].J Clin Exp Hematop, 2011, 51:21-28.
[2]	KASE S, NAMBA K, KITAICHI N, et al.Epstein-Barr virus infected cells in the aqueous humour originated from nasal NK/T cell lymphoma[J].Br J Ophthal, 2006, 90:244-245.
[3]	CHAN J K, YIP T T, TSANG W Y, et al.Detection of Epstein-Barr viral RNA in malignant lymphomas of the upper aerodigestive tract[J].Am J Surg Pathol, 1994, 18:938-946.
[4]	KO Y H, CHO E Y, KIM J E, et al.NK and NK-like T-cell lymphoma in extranasal sites a comparative clinicpathological study according to site and EBV status[J].Histopathology, 2004, 44:480-489.
[5]	AU W Y, PANG A, CHOY C, et al.Quantification of circulating Epstein-Barr virus DNA in the diagnosis and monitoring of natural killer cell and EBV positive lymphomas in immunocompetent patients[J].Blood, 2004, 104:243-249.
[6]	SAHARA N, TAKESHITA A, SHIGENO K, et al.Clinicopathological and prognostic characteristics of CD56-negative multiple myeloma[J].Br J Haematol, 2002, 117:882-885.
[7]	CHIM C S, MA S Y, AU W Y, et al.Primary nasal natural killer cell lymphoma:long-term treatment outcome and relationship with the international Prognostic Index[J].Blood, 2004, 103:216-221.
[8]	LEE J, SU H C, PARK Y H, et al.Extranodal natural killer T-cell lymphoma, nasal type a prognostic model from a retrospective multicenter study[J].J Clin Oncol, 2006, 24:612-618.
[9]	YAMAGUCHI M, TOBINAI K, OGUCHI M, et al.Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma:Japan Clinical Oncology Group Study JCOG0211[J].J Clin Oncol, 2009, 27:5594-5600.
[10]	JACCARD A, PETIT B, GIRAULT S, et al.L-asparaginase-based treatment of 15 western patients with exreanodal NK/T-cell lymphoma and leukemia and a review of the literature[J].Ann Oncol, 2009, 20:110-116.
[11]	YAMAGUCHI M, SUZUKI R, KWONG Y L, et al.Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide(SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal killer(NK)/T-cell lymphoma and leukemia[J].Cancer Sci, 2008, 99:1016-1020.